CellGenix® rh TNF-α (GMP grade)
Top Features for Recombinant Tumor Necrosis Factor-alpha:
- Optimal use of maturation of iDC's
- ADCF Level 2
- High purity to ensure the safety of your process
- Available in two different grades (Preclinical and GMP grade)
Preclinical grade:
- Intended for preclinical ex vivo use
- GMP transferable: Seamless transition from preclinical development to commercial manufacturing
GMP grade:
- Intended for clinical ex vivo use
- Endotoxin Level ≤ 50 EU/mg
- Manufactured in accordance with applicable GMP guidelines
- FDA Drug Master File (DMF) available
- Technical and regulatory support available
- Catalog No.:
- 1006-050
*Custom/bulk order quotes are provided within 72 hours of request.
Letter of Authorization (LOA)
Place a request for a Letter of Authorization (LOA) for our Drug Master File (FDA)
CellGenix® rh Cytokines - Preclinical vs GMP
Both product grades are produced under the same conditions in a GMP facility, ensuring an equal product quality and performance. We offer a more comprehensive QC testing including tighter specifications and documentation for our GMP products: CellGenix® rh Cytokines - Preclinical vs GMP
Choose your CellGenix® Growth Factors and Cytokines
CellGenix® Recombinant Human Tumor Necrosis Factor-alpha (TNF-α) is an animal-derived component-free product. It is produced in a dedicated animal-free GMP facility. TNF-α is used in the cell and gene therapy space for the ex vivo maturation of immature dendritic cells (iDCs) into mature dendritic cells.
CellGenix® Recombinant Human TNF-α is produced following all applicable GMP guidelines and allows for the safe use in accordance with USPChapter <1043>, Ph. Eur. General Chapter 5.2.12 and ISO 20399:2022.
CellGenix® GMP cytokines are provided with documented evidence of purity, potency, consistency and stability. In combination with our expert regulatory and technical support this will help simplify your raw material qualification and validation efforts.
Expiry: ≥ 6 months from date of shipping
Please refer to Certificate of Analysis https://my.sartorius.com/login for the exact expiry date and the batch specific activity.
We have submitted Drug Master Files (DMFs) to US Health Authorities to support our customers’ regulatory activities. These Master Files can be cross-referenced through Letters of Authorization (LOAs) in Marketing Authorizations, IND, BLA, NDA, ANDA or other DMF applications. Submit your Authorization Request here https://cellgenix.com/dmf-letter-of-authorization-request-form-2/
Applications
-
ApplicationClinical ex vivo use (small)
-
Application Area
-
Cell & Gene Therapy
-
Epithelial Cell Biology
- Immunology
-
Cell & Gene Therapy
-
Cell TypeDC
Biological Information
-
Activity20 – 80 x 106 IU/mg
Compliance Information
-
GMP ComplianceThis product was manufactured in accordance with applicable Good Manufacturing Practice (GMP) guidelines.
-
OriginAnimal-Component Free
Physicochemical Information
-
Endotoxin≤ 50 EU/mg
-
ExpressionE. coli
-
FormulationLyophilized from 200 µl of a 0.2 µm-filtered solution containing 1.5 mM potassium phosphate, 8.1 mM sodium phosphate, 2.7 mM potassium chloride and 137 mM sodium chloride, pH 7.5
Product Information
-
BrandCellGenix®
-
Package TypeVial
Sterility
-
Delivery ConditionSterile
-
Purity≥ 97%
Volumes
-
Volume50 µg
Weights
-
Molecular Weight (kDa)17.5 kDa